Astbury C, Beyeler C, Bird H A
Clinical Pharmacology Unit, Chapel Allerton Hospital, Leeds, West Yorkshire, UK.
Rheumatol Int. 1995;14(6):257-60. doi: 10.1007/BF00262093.
Acetylation polymorphisms have been linked with a tendency to develop rheumatic diseases. We investigated the effect of changes in the disease activity of patients with rheumatoid arthritis (RA) during disease-modifying antirheumatic drug (DMARD) treatment, and on the capacity of these patients to acetylate the sulphonamide sulphadimidine. Fifty-four patients with RA treated with gold, sulphasalazine or D-penicillamine, 12 patients with AS and 16 patients with non-inflammatory arthritis (NI) were investigated over a 24-week period. The capacity of these individuals to acetylate sulphadimidine was determined at baseline and after 12 and 24 weeks. Although there was a tendency for sulphadimidine acetylation to increase in patients with RA from a median of 84.5% [interquartile range (IQR) 77.0-95.0%] at baseline to 90.5% (IQR 77.5-96.0%) at week 24, this failed to reach statistical significance. In contrast, the trend in patients with AS or NI was towards a decrease in acetylation. There was no correlation between changes in disease activity and sulphadimidine acetylation during DMARD intervention.
乙酰化多态性与患风湿性疾病的倾向有关。我们研究了类风湿关节炎（RA）患者在使用改善病情抗风湿药（DMARD）治疗期间疾病活动度变化的影响，以及这些患者对磺酰胺类药物磺胺二甲嘧啶的乙酰化能力。在24周的时间里，对54例接受金制剂、柳氮磺胺吡啶或青霉胺治疗的RA患者、12例强直性脊柱炎（AS）患者和16例非炎性关节炎（NI）患者进行了研究。在基线时以及12周和24周后测定了这些个体对磺胺二甲嘧啶的乙酰化能力。尽管RA患者中磺胺二甲嘧啶乙酰化有从基线时中位数84.5%[四分位间距（IQR）77.0 - 95.0%]增加到第24周时90.5%（IQR 77.5 - 96.0%）的趋势，但这未达到统计学显著性。相比之下，AS或NI患者的乙酰化趋势是下降。在DMARD干预期间，疾病活动度变化与磺胺二甲嘧啶乙酰化之间没有相关性。
